Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Clinical and Experimental Nephrology
Published in: Clinical and Experimental Nephrology 5/2013

01-10-2013 | Review Article

Antineutrophil cytoplasmic autoantibody-associated vasculitis in Chinese patients

Authors: Peng-cheng Xu, Min Chen, Ming-hui Zhao

Published in: Clinical and Experimental Nephrology | Issue 5/2013

Login to get access

Abstract

Antineutrophil cytoplasmic autoantibody (ANCA)-associated vasculitis (AAV) is a common autoimmune disease in China. AAVs in the majority of Chinese patients are microscopic polyangiitis with antigenicity to myeloperoxidase. Propylthiouracil is the leading cause of drug-induced AAV. The genetic background and immunological characteristics of ANCA, such as the epitope, IgG subclass and avidity, might contribute to various clinical phenotypes of AAV.
Literature
1.
Watts RA, Lane SE, Scott DG, Koldingsnes W, Nossent H, Gonzalez-Gay MA, et al. Epidemiology of vasculitis in Europe. Ann Rheum Dis. 2001;60:1156–7.PubMedCrossRef
2.
Xin G, Zhao MH, Wang HY. Detection rate and antigenic specificities of antineutrophil cytoplasmic antibodies in Chinese patients with clinically suspected vasculitis. Clin Diagn Lab Immunol. 2004;11:559–62.PubMed
3.
Chen M, Yu F, Zhang Y, Zhao MH. Clinical and pathological characteristics of Chinese patients with antineutrophil cytoplasmic autoantibody associated systemic vasculitides: a study of 426 patients from a single centre. Postgrad Med J. 2005;81:723–7.PubMedCrossRef
4.
Chen M, Yu F, Zhang Y, Zou WZ, Zhao MH, Wang HY. Characteristics of Chinese patients with Wegener’s granulomatosis with anti-myeloperoxidase autoantibodies. Kidney Int. 2005;68:2225–9.PubMedCrossRef
5.
Chen M, Yu F, Zhang Y, Zhao MH. Antineutrophil cytoplasmic autoantibody-associated vasculitis in older patients. Medicine (Baltimore). 2008;87:203–9.CrossRef
6.
Xu PC, Chen M, Zhao MH. High potential to reverse the inhibition of myeloperoxidase by ceruloplasmin of anti-myeloperoxidase autoantibodies of IgG3 subclass. Autoimmunity. 2012;45:218–25.PubMedCrossRef
7.
Zhang AH, Chen M, Gao Y, Zhao MH, Wang HY. Inhibition of oxidation activity of myeloperoxidase (MPO) by propylthiouracil (PTU) and anti-MPO antibodies from patients with PTU-induced vasculitis. Clin Immunol. 2007;122:187–93.PubMedCrossRef
8.
Xu PC, Chen M, Cui Z, Zhao MH. Influence of myeloperoxidase by anti-myeloperoxidase antibodies and its association with the disease activity in microscopic polyangiitis. Rheumatology (Oxford). 2010;49:2068–75.CrossRef
9.
Xu PC, Gou SJ, Yang XW, Cui Z, Jia XY, Chen M, et al. Influence of variable domain glycosylation on anti-neutrophil cytoplasmic autoantibodies and anti-glomerular basement membrane autoantibodies. BMC Immunol. 2012;9(13):10.CrossRef
10.
Cui Z, Zhao MH, Segelmark M, Hellmark T. Natural autoantibodies to myeloperoxidase, proteinase 3, and the glomerular basement membrane are present in normal individuals. Kidney Int. 2010;78:590–7.PubMedCrossRef
11.
Xu PC, Cui Z, Chen M, Hellmark T, Zhao MH. Comparison of characteristics of natural autoantibodies against myeloperoxidase and anti-myeloperoxidase autoantibodies from patients with microscopic polyangiitis. Rheumatology (Oxford). 2011;50:1236–43.CrossRef
12.
Willcocks LC, Lyons PA, Rees AJ, Smith KG. The contribution of genetic variation and infection to the pathogenesis of ANCA-associated systemic vasculitis. Arthritis Res Ther. 2010;12:202.PubMedCrossRef
13.
Luo H, Chen M, Yang R, Xu PC, Zhao MH. The association of HLA-DRB1 alleles with antineutrophil cytoplasmic antibody-associated systemic vasculitis in Chinese patients. Hum Immunol. 2011;72:422–5.PubMedCrossRef
14.
Chang DY, Luo H, Zhou XJ, Chen M, Zhao MH. Association of HLA genes with clinical outcomes of ANCA-associated vasculitis. Clin J Am Soc Nephrol. 2012;7:1293–9.PubMedCrossRef
15.
Gao Y, Chen M, Ye H, Guo XH, Zhao MH, Wang HY. The target antigens of antineutrophil cytoplasmic antibodies (ANCA) induced by propylthiouracil. Int Immunopharmacol. 2007;7:55–60.PubMedCrossRef
16.
Gao Y, Zhao MH, Guo XH, Xin G, Gao Y, Wang HY. The prevalence and target antigens of antithyroid drugs induced antineutrophil cytoplasmic antibodies (ANCA) in Chinese patients with hyperthyroidism. Endocr Res. 2004;30:205–13.PubMedCrossRef
17.
Zhao MH, Chen M, Gao Y, Wang HY. Propylthiouracil-induced anti-neutrophil cytoplasmic antibody-associated vasculitis. Kidney Int. 2006;69:1477–81.PubMed
18.
Yu F, Chen M, Gao Y, Wang SX, Zou WZ, Zhao MH, et al. Clinical and pathological features of renal involvement in propylthiouracil-associated ANCA-positive vasculitis. Am J Kidney Dis. 2007;49:607–14.PubMedCrossRef
19.
Chen M, Gao Y, Guo XH, Zhao MH. Propylthiouracil-induced antineutrophil cytoplasmic antibody-associated vasculitis. Nat Rev Nephrol. 2012;8:476–83.PubMedCrossRef
20.
Gao Y, Ye H, Yu F, Guo XH, Zhao MH. Anti-myeloperoxidase IgG subclass distribution and avidity in sera from patients with propylthiouracil-induced antineutrophil cytoplasmic antibodies associated vasculitis. Clin Immunol. 2005;117:87–93.PubMedCrossRef
21.
Liu LJ, Chen M, Yu F, Zhao MH, Wang HY. IgG subclass distribution, affinity of anti-myeloperoxidase antibodies in sera from patients with Wegener’s granulomatosis and microscopic polyangiitis. Nephrology (Carlton). 2008;13:629–35.CrossRef
Metadata
Title
Antineutrophil cytoplasmic autoantibody-associated vasculitis in Chinese patients
Authors
Peng-cheng Xu
Min Chen
Ming-hui Zhao
Publication date
01-10-2013
Publisher
Springer Japan
Published in
Clinical and Experimental Nephrology / Issue 5/2013
Print ISSN: 1342-1751
Electronic ISSN: 1437-7799
DOI
https://doi.org/10.1007/s10157-012-0702-7

Other articles of this Issue 5/2013

Clinical and Experimental Nephrology 5/2013 Go to the issue

Review Article

Clinical trial for Japanese patients with myeloperoxidase anti-neutrophil cytoplasmic antibody-associated vasculitis: the JMAAV study

Review Article

The role of myeloperoxidase and myeloperoxidase–antineutrophil cytoplasmic antibodies (MPO-ANCAs) in the pathogenesis of human MPO-ANCA-associated glomerulonephritis

Review Article

Limited pulmonary MPA, a new MPA entity? A rheumatologist’s perspective

Review Article

Kawasaki disease: basic and pathological findings

Review Article

Complement in antineutrophil cytoplasmic antibody-associated vasculitis

Review Article

Vasculitis: report from Mexico
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits